India, July 29 -- Biocon Ltd has announced that its Canadian subsidiary has received Health Canada's Notice of Compliance (NOC) for Yesintek® (ustekinumab) Autoinjector in 45 mg/0.5 mL and 90 mg/mL strengths.
The approval expands Biocon's immunology portfolio in Canada, following the regulatory clearance granted in October 2025 for Yesintek® prefilled syringes, vials, and intravenous infusion formulations.
The newly approved autoinjector offers Canadian patients a self-administration option that is not available with the originator product, enabling more personalized treatment across different care settings.
Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, ...